Companies / Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc.

MRSNCIK 1442836CAMBRIDGE, MAmersana.com ↗

Financials · FY2024

Revenue$40.50M
Net income$-69.19M
Total debt$2.08M
Cash$56.39M
Diluted EPS$-0.56
Shares outstanding5.0M

Ownership

5.0M shares outstanding · as of Nov 7, 2025
4.2%10%+ / strategic
Ownership
10%+ / strategic4.21%210,301
Public float95.79%4,788,449

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 13

View all →
Insider% of sharesShares
Alleva Lawrence MDirector
0.00%0
Bala MohanSVP, Chief Development
0.00%0
Carvajal AlejandraSVP, Chief Legal Officer
0.00%0
Dere Willard HDirector
0.00%0
DeSchuytner BrianSVP, COO & CFO
0.00%0
Diaz Allene M.Director
0.00%0
Hack Andrew A. F.Director
0.00%0
Hege KristenDirector
0.00%0
Huber Martin H. Jr.CEOPresident, CEO · Director
0.00%0
Lowinger Timothy BSVP, Chief Sci.&Tech. Officer
0.00%0

Institutional holders 0

HolderValue% of shares
No institutional holders on file.

Activity

—View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
No activity matches these filters.

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—210,301—
683 Capital Management, LLCPassive13G/A———
Nextech Crossover I GP S.a. r.l.Passive13G/A———
Schonfeld Strategic Advisors LLCPassive13G/A———